This will be of interested to my clinical, bioanalytical, pharmacokinetic and pharmacovigilance colleagues.
From the FDA e-mail announcement:
"FDA, UK's Medicines and Healthcare products Regulatory Agency and Health Canada will host a joint symposium, Regulatory Perspectives in Good Clinical Practice, Bioequivalence and Good Pharmacovigilance Practice, June 2-4, 2026. This hybrid event will take place in Ottawa with options for virtual attendance.
This symposium will highlight current and emerging topics of interest related to good clinical practice, bioequivalence and good pharmacovigilance practice. The event will bring together regulators, investigators, clinical researchers, clinical trial staff, sponsors, research organizations, service providers, pharmaceutical and biotechnology companies, academics and patient advocacy groups. Participants will hear directly from regulatory experts on ICH E6(R3) implementation, innovative trial design, bioequivalence case studies and international collaboration on pharmacovigilance compliance. "
Register here: https://events.myconferencesuite.com/joint_us-fda_uk-mhra_health_canada_gcp-be-gvp/reg/form/edit
#fda #HealthCanada #MHRA #GCP #BE #CPP
------------------------------
Mark Arnold Ph.D., FAAPS
Westampton, NJ
[email protected]Bioanalytical Solution Integration
LinkedIn:
https://www.linkedin.com/in/markearnoldphd/Website & Blog: Bioanalysis & Biomarkers <bioanalysisandbiomarkers.blogspot.com>
------------------------------
</bioanalysisandbiomarkers.blogspot.com>